{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:21:41Z","timestamp":1782274901782,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116742","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:32:17Z","timestamp":1776011537000},"page":"116742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC"],"prefix":"10.1016","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0537-3884","authenticated-orcid":false,"given":"Barend J.","family":"Sikkema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijn","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Oomen-de","family":"Hoop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-6195","authenticated-orcid":false,"given":"Marthe S.","family":"Paats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116742_bib1","volume":"v1.3","author":"ESMO","year":"2026"},{"key":"10.1016\/j.ejca.2026.116742_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116742_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/ijc.34742","article-title":"Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer","volume":"154","author":"van Veelen","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","article-title":"Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index","volume":"31","author":"Martin","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116742_bib5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/JTO.0000000000000690","article-title":"Prognostic significance of CT-determined sarcopenia in patients with small-cell lung cancer","volume":"10","author":"Kim","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116742_bib6","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: results from a prospective, observational study","volume":"10","author":"Rounis","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ejca.2026.116742_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1471-2407-13-158","article-title":"Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review","volume":"13","author":"Jafri","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib8","article-title":"A low advanced lung cancer inflammation index predicts a poor prognosis in patients with metastatic non-small cell lung cancer","volume":"8","author":"Lu","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.ejca.2026.116742_bib9","unstructured":"EMA. TAGRISSO: EPAR - Product Information. 2016.."},{"key":"10.1016\/j.ejca.2026.116742_bib10","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.21873\/invivo.13376","article-title":"The relationship between efficacy and safety of osimertinib blood concentration in patients with EGFR mutation-positive lung cancer: a prospective observational study","volume":"37","author":"Hashino","year":"2023","journal-title":"Vivo"},{"key":"10.1016\/j.ejca.2026.116742_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116742_bib12","doi-asserted-by":"crossref","DOI":"10.3945\/ajcn.2010.28608C","article-title":"Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis","volume":"91","author":"Baracos","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ejca.2026.116742_bib13","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.lungcan.2019.05.021","article-title":"The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer","volume":"133","author":"Degens","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/jcsm.12698","article-title":"The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab","volume":"12","author":"Degens","year":"2021","journal-title":"J Cachex-- Sarcopenia Muscle"},{"key":"10.1016\/j.ejca.2026.116742_bib15","first-page":"223","article-title":"Systemic inflammation, nutritional status and survival in patients with cancer","volume":"12","author":"McMillan","year":"2009","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.ejca.2026.116742_bib16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","article-title":"A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times","volume":"31","author":"Wang","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ejca.2026.116742_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/1759-7714.12545","article-title":"Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer","volume":"9","author":"Kakinuma","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib19","first-page":"853","article-title":"Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival","volume":"26","author":"Kucukarda","year":"2021","journal-title":"J Buon"},{"key":"10.1016\/j.ejca.2026.116742_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116742_bib21","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2023.03.020","article-title":"Analysis of serious weight gain in patients using alectinib for ALK-positive lung cancer","volume":"18","author":"de Leeuw","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2026.116742_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.diff.2025.100862","article-title":"The mechanism of EGF in promoting skeletal muscle post-injury regeneration","volume":"143","author":"Teng","year":"2025","journal-title":"Differentiation"},{"key":"10.1016\/j.ejca.2026.116742_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.stem.2019.01.002","article-title":"EGFR-Aurka signaling rescues polarity and regeneration defects in dystrophin-deficient muscle stem cells by increasing asymmetric divisions","volume":"24","author":"Wang","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ejca.2026.116742_bib24","first-page":"2657","article-title":"Early skeletal muscle loss in non-small cell lung cancer patients receiving chemoradiation and relationship to survival","volume":"27","author":"Kiss","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib25","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2024.1120","article-title":"Body composition in advanced non-small cell lung cancer treated with immunotherapy","volume":"10","author":"Chaunzwa","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116742_bib26","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1111\/1759-7714.13958","article-title":"Longitudinal changes in skeletal muscle mass in patients with advanced squamous cell lung cancer","volume":"12","author":"Lee","year":"2021","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ejca.2026.116742_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169136","article-title":"Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients","volume":"12","author":"Nattenm\u00fcller","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2026.116742_bib28","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.clnu.2014.03.006","article-title":"Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial","volume":"33","author":"S\u00e1nchez-Lara","year":"2014","journal-title":"Clin Nutr"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600523X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492600523X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:22:28Z","timestamp":1779294148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492600523X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S095980492600523X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116742","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Associations between early loss of skeletal muscle and osimertinib trough concentrations in patients with advanced EGFR-mutated NSCLC","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116742"}}